Unidad de Investigación Clínica de Cáncer de Mama

Miguel Angel Quintela Jefe de Unidad de Investigación Clínica
T +34 917328000 (Ext 2930)
mquintela@cnio.es

Investigadores

Becarios Post-doctorales

Rebeca Gema Jimeno

Becarios Pre-Doctorales

José Luis Ruiz

Técnicos de Laboratorio

The Breast Cancer Clinical Research Unit (BCCRU) focuses on the translational interface of therapeutic development. Breast cancer is a heterogeneous disease and, thus, there are large inter-patient variations in terms of disease course, prognosis, relapse and resistance to conventional or targeted therapeutics.

Our activities are directed towards personalised treatment, and they range from preclinical models to the sponsoring of multicentric clinical trials. Specifically, our research areas are:

Discovery of new targets for breast cancer prevention.
Breast cancer functional taxonomy: by using a systems biology approach, we are clustering the disease into subtypes defined by biological features that constitute therapeutic targets.
Study of the mechanisms of resistance against targeted therapies.

Publicaciones

Mestre-Farrera A, Bruch-Oms M, Peña R, Rodríguez-Morató J, Alba-Castellón L, Cormena L, Quintela-Fandino M, Duñach M, Baulida J, Pozo OJ, García de Herreros A (2021). Glutamine-Directed Migration of Cancer-Activated Fibroblasts Facilitates Epithelial Tumor Invasion. Cancer Res 81, 438-451. Publicación CNIO.
Colomer R, Mondejar R, Romero-Laorden N, Alfranca A, Sanchez-Madrid F, Quintela-Fandino M (2020). When should we order a next generation sequencing test in a patient with cancer?. EClinicalMedicine 25, 100487. Publicación CNIO. Open Access
Quintela-Fandino M, Morales S, Cortés-Salgado A, Manso L, Apala JV, Muñoz M, Gasol Cudos A, Salla Fortuny J, Gion M, Lopez-Alonso A, Cortés J, Guerra J, Malón D, Caleiras E, Mulero F, Mouron S (2020). Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer.. Clin Cancer Res 26, 35-45. Publicación CNIO.
Grunt TW, Slany A, Semkova M, Colomer R, López-Rodríguez ML, Wuczkowski M, Wagner R, Gerner C, Stübiger G (2020). Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer. Sci Rep 10, 14877. Publicación CNIO. Open Access
Moreno-Lama L, Galindo-Campos MA, Martínez C, Comerma L, Vazquez I, Vernet-Tomas M, Ampurdanés C, Lutfi N, Martin-Caballero J, Dantzer F, Quintela-Fandino M, Ali SO, Jimeno J, Yélamos J (2020). Coordinated signals from PARP-1 and PARP-2 are required to establish a proper T cell immune response to breast tumors in mice. Oncogene 39, 2835-2843. Publicación CNIO.
Quintela-Fandino M, Holgado E, Manso L, Morales S, Bermejo B, Colomer R, Apala JV, Blanco R, Muñoz M, Caleiras E, Iranzo V, Martinez M, Dominguez O, Hornedo J, Gonzalez-Cortijo L, Cortes J, Gasol Cudos A, Malon D, Lopez-Alonso A, Moreno-Ortíz MC, Mouron S, Mañes S (2020). Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. Breast Cancer Res 22, 124. Publicación CNIO. Open Access
Calvete O, Mouron S, Barroso A, Soberon N, Blasco MA , Quintela-Fandino M, Benítez J (2020). Long telomeres: A new prognostic factor for severity in triple-negative breast cancer patients. J Transl Sci (in press). Publicación CNIO.
Bueno MJ, Jimenez-Renard V, Samino S, Capellades J, Junza A, López-Rodríguez ML, Garcia-Carceles J, Lopez-Fabuel I, Bolaños JP, Chandel NS, Yanes O, Colomer R, Quintela-Fandino M (2019). Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells.. Nat Commun 10, 5011. Publicación CNIO. Open Access
Morales ML, Arenas A, Ortiz-Ruiz A, Leivas A, Rapado I, Rodríguez-García A, Castro N, Zagorac I, Quintela-Fandino M, Gómez-López G, Gallardo M, Ayala R, Linares M, Martinez-Lopez J (2019). MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia. Sci Rep 9, 18630. Publicación CNIO. Open Access
Zagorac I, Fernandez-Gaitero S, Penning R, Post H, Bueno MJ, Mouron S, Manso L, Morente MM, Alonso S, Serra V, Muñoz J, Gómez-López G, Lopez-Acosta JF, Jimenez-Renard V, Gris-Oliver A, Al-Shahrour F, Piñeiro-Yañez E, Montoya-Suarez JL, Apala JV, Moreno-Torres A, Colomer R, Dopazo A, Heck AJR, Altelaar M, Quintela-Fandino M (2018). In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. Nat Commun 9, 3501. Publicación CNIO. Open Access
Álvarez-Fernández M, Sanz-Flores M, Sanz-Castillo B, Salazar-Roa M, Partida D, Zapatero-Solana E, Ali HR, Manchado E, Lowe S, VanArsdale T, Shields D, Caldas C, Quintela-Fandino M, Malumbres M (2018). Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer. Cell Death Differ 25, 828-840. Publicación CNIO.
Quintela-Fandino M, Lluch A, Manso LM, Calvo I, Cortes J, Garcia Saenz JA, Gil JM, Martinez-Jez N, Gonzalez Martin A, Adrover E, De Andres R, Viñas G, Llombart-Cussac A, Alba E, Guerra K, Bermejo B, Zamora E, Moreno-Anton F, Pernas Simón S, Carrato A, Lopez A, Escudero MJ, Campo R, Carrasco EM, Palacios J, Mulero F, Colomer R (2017). 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: a window-of-opportunity randomized trial.. Clin Cancer Res 23, 1432-1441. Publicación CNIO.
Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer. (2017). Álvarez-Fernández M, Sanz-Flores M, Sanz-Castillo B, Salazar-Roa M, Partida D, Zapatero-Solana E, Ali HR, Manchado E, Lowe S, VanArsdale T, Shields D, Caldas C, Quintela-Fandino M, Malumbres M.. Cell Death Differ (in press). Publicación CNIO.
Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA. (2017). Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.. Oncogene 36, 2737-2749. Publicación CNIO.
Bueno MJ, Mouron S, Quintela-Fandino M. (2017). Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach.. Br J Cancer 116, 1119-1125. Publicación CNIO.
Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, Cortes J, Moreno-Antón F, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Mouron S, Guerra J, Bermejo B, Zamora E, García-Saenz JA, Simon SP, Carrasco E, Escudero MJ, Campo R, Colomer R, Blasco MA (2017). Critically short telomeres and toxicity of chemotherapy in early breast cancer. Oncotarget 8, 21472-21842. Publicación CNIO.
Mateo F, Arenas E, Aguilar H, Serra-Musach J, Ruiz de Garibay G, Boni J, Maicas M, Du S, Iorio F, Herranz C, Isam A, Prado X, Llorente A, Petit A, Vidal A, Catala I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts A, Weerd V, Look MP, Puertas S, GArcia N, Perkins AS, Bonifaci N, Skowron M, Gomez-Baldo L, Hernandez V, Martinez A, Martinez-Iniesta M, Serrat X, Ceron J, Brunet J, Barretina MP, Gil M, Falo C, Fernandez A, Morilla I, Pernas S, Pla MJ, Andreu X, Seguí MA, Ballester R, Castellá E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Sanchez-Mut JV, Gonzalez-Suarez E, Cordero A, Sanchez Cespedes M, Gajewski TF,Cohen EEZ, Jesiotr M, Bodnar L, Quintela-Fandino M, Lopez-Bigas N, Viñals F, Casanovas O, Graupera M, Hernandez-Losa J, Ramon y Cajal S, Saez-Rodriguez J, Esteller M, Sierra A, Martin-Martin N, Matheu A, Carracedo A, Nanjundan M, Cortes J, Odero M, Lazaro C, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA (2016). Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.. Oncogene (in press). Publicación CNIO.
Hernández-Agudo E, Mondejar T, Soto-Montenegro ML, Megías D, Mouron S, Sanchez J, Hidalgo M, Lopez-Casas PP, Mulero F, Desco M, Quintela-Fandino M (2016). Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET. Mol Oncol 10, 1704-1718. Publicación CNIO. Open Access
Manso L, Mourón S, Tress M, Gómez-López G, Morente M, Ciruelos E, Rubio-Camarillo M, Rodriguez-Peralto JL, Pujana MA, Pisano DG, Quintela-Fandino M (2016). Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance.. PLoS ONE 11, e0155840. Publicación CNIO.
Bueno M, Sanchez J, Colomer R, Quintela-Fandino M. (2016). Antiangiogenics and hypoxic response: Role of fatty acid synthase inhibitors.. Curr Drug Targets 17, 1735-1746. Publicación CNIO.
Ebos J, Quintela-Fandino M (2016). Revisiting the revolution: examining the evolving role of antiangiogenic therapy in cancer.. Curr Drug Targets 17, 1706. Publicación CNIO.
Lord S, Funes JM, Harris AL, Quintela-Fandino M (2016). Antiangiogenic resistance and cancer metabolism: opportunities for synthetic lethality.. Curr Drug Targets 17, 1714-1727. Publicación CNIO.
Navarro P, Bueno MJ, Zagorac I, Mondejar T, Sanchez J, Mourón S, Muñoz J, Gómez-López G, Jimenez-Renard V, Mulero F, Chandel NS, Quintela-Fandino M (2016). Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics. Cell Reports 15, 2705-2718. Publicación CNIO. Open Access